

The General Manager, Pakistan Stock Exchange Limited, Stock Exchange Building, Stock Exchange Road, KARACHI.

Subject:

FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2021

Dear Sir,

It is to inform you that the Board of Directors of our Company in the meeting held on Friday, October 22, 2021, at 11:00 a.m., at Corporate Office, (Office No. 901, 9th Floor, Tricon Corporate Center, 73 E, Jail Road, Lahore) approved the financial statements for the 3<sup>rd</sup> Quarter ended September 30, 2021.

Financial Results of the Company and Consolidated Financial Results with its subsidiary are attached herewith as Annexure I and Annexure II respectively.

The Quarterly Report of the Company for the period ended September 30, 2021, will be transmitted through PUCARS separately, within the specified time.

Thanking you and assurances of our highest considerations.

Yours faithfully,

KHADIM HUSSAIN MIRZA, Company Secretary

- The Securities & Exchange Commission of Pakistan, Islamabad
- The Securities & Exchange Commission of Pakistan, Companies Registration Office, Lahore.



## Annexure I

## HIGHNOON LABORATORIES LIMITED UNCONSOLIDATED CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (UN-AUDITED) FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2021

	Nine Month P	eriod Ended	Three Month Period Ended		
	30 September	30 September	30 September	30 September	
	2021	2020	2021	2020	
	Rupees	Rupees	Rupees	Rupees	
Revenue from Contract with customers- net	9,579,542,055	7,899,231,624	3,209,577,357	2,842,361,967	
Cost of revenue	(4,830,388,545)	(4,046,349,200)	(1,614,549,880)	(1,441,476,878)	
Gross profit	4,749,153,510	3,852,882,424	1,595,027,477	1,400,885,089	
Distribution, selling and promotional expenses	(2,588,825,376)	(2,084,852,251)	(893,916,452)	(777,915,154)	
Administrative and general expenses	(412,276,696)	(324,641,350)	(165,461,325)	(119,324,218)	
Research and development expenses	(6,692,184)	(4,792,497)	(2,087,777)	(2,042,519)	
Other operating expenses	(148,522,155)	(124,787,130)	(38,158,289)	(47,204,703)	
	(3,156,316,411)	(2,539,073,228)	(1,099,623,843)	(946,486,594)	
Operating profit	1,592,837,099	1,313,809,196	495,403,634	454,398,495	
Other income	114,284,214	59,347,133	41,276,057	18,751,202	
Finance costs	(17,166,428)	(10,848,799)	(2,363,181)	(7,719,610)	
Profit before taxation	1,689,954,885	1,362,307,530	534,316,510	465,430,087	
Taxation	(462,823,212)	(384,380,069)	(157,215,627)	(139,148,899)	
Profit for the period	1,227,131,673	977,927,461	377,100,883	326,281,188	
		Restated		D4-4-1	
Earnings per share - basic and diluted	32.23		0.00	Restated	
=	32.23	25.68	9.90	8.57	





Earnings per share - basic and diluted

## Annexure II

Three Month Period Ended

Restated

9.15

## HIGHNOON LABORATORIES LIMITED CONSOLIDATED CONDENSED INTERIM STATEMENT OF PROFIT OR LOSS (Un-audited) FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2021

	30 September 2021	30 September 2020	30 September 2021	30 September 2020
	Rupees	Rupees	Rupees	Rupees
Revenue from Contract with customers- net Cost of revenue	9,579,542,055 4,737,445,241	7,899,231,624	3,209,577,357	2,842,361,967
Gross profit	4,842,096,814	3,966,841,126 3,932,390,498	1,581,712,879 1,627,864,478	1,400,517,498 1,441,844,469
Distribution, selling and promotional expenses	2,588,825,376	2,084,852,251	893,916,452	777,915,154
Administrative and general expenses	440,113,807	345,914,144	173,778,677	127,287,241
Research and development expenses	6,692,184	4,792,497	2,087,777	2,042,519
Other operating expenses	152,665,328	127,963,697	40,354,752	49,782,093
	3,188,296,695	2,563,522,589	1,110,137,658	957,027,007
Operating Profit	1,653,800,119	1,368,867,909	517,726,820	484,817,462
Other income	113,342,697	58,405,616	40,757,095	18,546,764
Finance costs	(21,540,625)	(17,167,600)	(3,054,170)	(9,686,143)
Profit before taxation	1,745,602,191	1,410,105,925	555,429,745	493,678,083
Taxation	(476,758,645)	(392,589,398)	(164,656,961)	(145,302,648)
Profit for the period	1,268,843,546	1,017,516,527	390,772,784	348,375,435

Nine Month Period Ended



10.26

Restated

26.72

33.32